Compare Divis Laboratories with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs BIOCON - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES BIOCON DIVIS LABORATORIES/
BIOCON
 
P/E (TTM) x 34.2 22.4 152.3% View Chart
P/BV x 6.4 3.0 213.9% View Chart
Dividend Yield % 1.0 0.4 246.7%  

Financials

 DIVIS LABORATORIES   BIOCON
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
BIOCON
Mar-18
DIVIS LABORATORIES/
BIOCON
5-Yr Chart
Click to enlarge
High Rs1,6391,188 138.0%   
Low Rs1,115305 365.6%   
Sales per share (Unadj.) Rs186.368.7 271.1%  
Earnings per share (Unadj.) Rs51.07.6 674.8%  
Cash flow per share (Unadj.) Rs57.314.0 410.3%  
Dividends per share (Unadj.) Rs16.001.00 1,600.0%  
Dividend yield (eoy) %1.20.1 867.3%  
Book value per share (Unadj.) Rs261.886.3 303.2%  
Shares outstanding (eoy) m265.47600.00 44.2%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x7.410.9 68.0%   
Avg P/E ratio x27.098.9 27.3%  
P/CF ratio (eoy) x24.053.4 45.0%  
Price / Book Value ratio x5.38.6 60.9%  
Dividend payout %31.413.2 237.1%   
Avg Mkt Cap Rs m365,592447,900 81.6%   
No. of employees `00011.86.1 192.7%   
Total wages/salary Rs m5,4239,311 58.2%   
Avg. sales/employee Rs Th4,175.16,705.8 62.3%   
Avg. wages/employee Rs Th457.71,514.2 30.2%   
Avg. net profit/employee Rs Th1,141.8736.9 155.0%   
INCOME DATA
Net Sales Rs m49,46341,234 120.0%  
Other income Rs m1,5562,062 75.5%   
Total revenues Rs m51,01943,296 117.8%   
Gross profit Rs m18,7188,291 225.8%  
Depreciation Rs m1,6893,851 43.9%   
Interest Rs m35615 5.7%   
Profit before tax Rs m18,5515,887 315.1%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,0231,569 320.2%   
Profit after tax Rs m13,5274,531 298.6%  
Gross profit margin %37.820.1 188.2%  
Effective tax rate %27.126.7 101.6%   
Net profit margin %27.311.0 248.9%  
BALANCE SHEET DATA
Current assets Rs m46,50141,486 112.1%   
Current liabilities Rs m8,46821,413 39.5%   
Net working cap to sales %76.948.7 158.0%  
Current ratio x5.51.9 283.5%  
Inventory Days Days13164 204.5%  
Debtors Days Days8694 91.2%  
Net fixed assets Rs m25,79750,661 50.9%   
Share capital Rs m5313,000 17.7%   
"Free" reserves Rs m68,96248,808 141.3%   
Net worth Rs m69,49351,808 134.1%   
Long term debt Rs m017,898 0.0%   
Total assets Rs m80,38399,897 80.5%  
Interest coverage x531.010.6 5,022.7%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.4 149.1%   
Return on assets %16.95.2 327.5%  
Return on equity %19.58.7 222.6%  
Return on capital %26.79.6 277.6%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,23812,058 342.0%   
Fx outflow Rs m12,4057,348 168.8%   
Net fx Rs m28,8334,710 612.2%   
CASH FLOW
From Operations Rs m9,5436,621 144.1%  
From Investments Rs m-6,854-6,840 100.2%  
From Financial Activity Rs m-2,459-2,397 102.6%  
Net Cashflow Rs m230-2,612 -8.8%  

Share Holding

Indian Promoters % 52.0 40.4 128.7%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 11.8 8.4 140.5%  
FIIs % 19.0 10.7 177.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 19.9 86.4%  
Shareholders   31,796 109,995 28.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 229 Points Lower; Banking and Metal Stocks Witness Selling(Closing)

Indian share markets fell sharply during closing hours today amid weak global cues and disappointing domestic factory output data.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Nov 13, 2019 03:37 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS